BD (Becton, Dickinson and Company) a leader in medical technology, will use BERG‘s artificial intelligence platform to improve patient health by minimizing challenges associated with medication adherence for patients. The partnership will leverage BD’s healthcare IT expertise and BERG’s AI platform to develop a medication adherence algorithm that will help healthcare workers identify certain patient populations that are at the highest risk for nonadherence post-discharge.
Estimates show that the cost of medication non-adherence in the United States is approximately $290 billion, equating to about 13% of total health care spending, or 2.3% of GDP. Providers in the US have a history of struggling with prescription compliance — resulting in patients not receiving the proper continued care.
Through this innovative solution, clinicians will be able to better prioritize patient interventions and engage the most appropriate ancillary staff to improve patient outcomes once they leave the hospital. BERG Analytics’ proprietary artificial intelligence-based platform bAIcis™ will be used to gather Patient Intelligence™ and develop custom risk models of medication non-adherence for a number of chronic and acute conditions to enhance BD’s MedMined™ solution for healthcare providers. BERG’s bAIcis(tm) analyzes data in a hypothesis free manner, discovering new knowledge in an unbiased and strictly data driven way. Overall, this will improve patient health and reduce costs from unnecessary re-admissions and doctor visits.
“We are at a tipping point in healthcare IT, where merging key technologies such as BERG data driven analytics platform and BD’s data mining expertise can provide more informed, precise solutions for clinicians,” said Niven R. Narain, Co-founder, President and CEO of BERG. “Utilizing these technologies to understand patient populations and offer clinical decision support will become the cornerstone of creating more efficient healthcare delivery.”
